Summary of Luminex Corporation (NASDAQ:LMNX) Ratings on Jun 29, 2018

June 29, 2018 - By Joseph Taylor

Luminex Corporation (NASDAQ:LMNX) Corporate Logo

Luminex Corporation (NASDAQ:LMNX) Ratings Coverage

Total analysts of 2 have positions in Luminex (NASDAQ:LMNX) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since January 5, 2018 according to StockzIntelligence Inc Luminex has 3 analyst reports. On Monday, May 7 the rating was upgraded by Deutsche Bank to “Hold”. Listed here are Luminex Corporation (NASDAQ:LMNX) PTs and latest ratings.

07/05/2018 Broker: Deutsche Bank Rating: Hold New Target: $22.0000 Upgrade
08/01/2018 Broker: BTIG Research Rating: Buy New Target: $24.0
05/01/2018 Broker: BTIG Research Rating: Buy New Target: $24 Initiates Coverage On

The stock increased 1.14% or $0.33 during the last trading session, hitting $29.21.Currently Luminex Corporation is uptrending after 33.74% change in last June 29, 2017. LMNX has 53,454 shares volume. The stock outperformed the S&P500 by 21.17%.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide.The firm is valued at $1.30 billion. The companyÂ’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform.The P/E ratio is 38.38. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

More recent Luminex Corporation (NASDAQ:LMNX) news were released by Globenewswire.com, Prnewswire.com and Streetinsider.com. The first one has “Detailed Research: Economic Perspectives on MGM Growth Properties, Acacia Research, Luminex, Eastman …” as a title and was released on June 20, 2018. The next is “Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay” on June 13, 2018. And last was released on June 13, 2018, called “Luminex Corp. (LMNX) Initiates Clinical Trials for VERIGENE II Gastrointestinal Assay”.

Luminex Corporation (NASDAQ:LMNX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.